Product Code: GDHC205PIDR
Ulcerative colitis (UC) is a type of inflammatory bowel disease. In UC, chronic inflammation affects the colon (also known as the large intestines). Initially, UC usually manifests in the terminal part of the colon, the rectum, and is termed ulcerative proctitis. It can extend to the entire left part of the colon (left-sided proctitis) or the entire colon (pancolitis). The current UC market is overcrowded with cheap generic drugs for mild to moderate disease, expensive biologics such as anti-tumor necrosis factors (TNFs) and anti-integrins, and biosimilars for severe disease that are used as short- or long-term alternatives to surgical options. The R&D within this space consists of 10 late-stage pipeline drugs with five oral formulations, more convenient dosing frequencies, novel mechanisms of action (MOAs), and improved safety profiles and drug availability. However, the pipeline products will be challenged by the increasing emergence of biosimilars, since the major brands will experience patent cliffs throughout the forecast period. Furthermore, all but one drug are being developed for moderate to severe UC, which will result in a crowded market.
This model covers the market forecast for the marketed and late-stage pipeline UC therapeutics. The model segments patients by severity, with mild-moderate, moderate-severe, and severe/fulminant segments. The base year of this model is 2019, and the forecast period is 2020-2029.
KEY QUESTIONS ANSWERED
- Which unmet needs are limiting the treatment of ulcerative colitis in the 8MM?
- What strategies can the pharmaceutical industry employ to increase treatment rates for ulcerative colitis? How should these strategies differ across different geographical markets?
- What effect will the launch of biosimilars and generics have on the sales of branded agents?
- What are the main R&D trends in the ulcerative colitis market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?
- The greatest drivers of growth in the global UC market include the launch of 10 new pipeline therapies during the forecast period and an increasing diagnosed prevalence in many 8MM countries.
- The main barriers to growth in the UC market include the crowded and competitive market as well as patent expiration of key biologic brands with subsequent biosimilar launch.
- Novel drug classes in the UC pipeline include IL-23 inhibitors and S1P receptor modulators. In addition, Takeda will launch a subcutaneous version of their product, Entyvio, and two additional JAK inhibitors are expected to make their appearance on the market.
- The most important unmet needs in the UC market are for safer and more effective therapies, an improvement in management of fulminant patients, biomarkers to predict responsiveness to therapy, and standardization of patient-reported outcomes.
- Overview of UC including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline UC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting UC therapeutics sales in the 8MM.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global UC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global UC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global UC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global UC therapeutics market from 2019-2029.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
2 Ulcerative Colitis: Executive Summary
- 2.1 Large Growth is Expected for UC Market from 2019-2029
- 2.2 Competition and Biosimilar Threat Defines UC Market
- 2.3 Pipeline Products Partially Address Unmet Needs
- 2.4 Opportunities for Managing Severe/Fulminant Patients Remain
- 2.5 Subcutaneous Biologics and Oral Therapies to Drive Growth in UC Market
- 2.6 What Do Physicians and Payers Think?
- 3.1 Catalyst
- 3.2 Related Reports
- 3.3 Upcoming Related Reports
4 Disease Overview
- 4.1 Etiology and Pathophysiology
- 4.2 Classification or Staging Systems
- 4.3 Symptoms
- 4.4 Quality of Life
- 5.1 Disease Background
- 5.2 Risk Factors and Comorbidities
- 5.3 Global and Historical Trends
- 5.4 Forecast Methodology
- 5.5 Epidemiological Forecast for UC (2019-2029)
- 5.6 Discussion
6 Disease Management
- 6.1 Diagnosis and Treatment Overview
- 6.2 Treatment Overview
- 6.3 Treatment Guidelines and Leading Prescribed Drugs
- 6.4 US
- 6.5 5EU
- 6.6 Japan
- 6.7 Canada
7 Competitive Assessment
- 7.1 Overview
- 7.2 KOL and Payer Opinion on the Impact of COVID-19
8 Unmet Needs and Opportunity Assessment
- 8.1 Overview
- 8.2 Lack of Safe and Efficacious Treatment Alternatives
- 8.3 Improved Medical Management for Severe/Fulminant Patients
- 8.4 Biomarkers to Predict Responsiveness to Therapy and Prognosis
- 8.5 Standardization of Patient-Reported Outcomes
9 Pipeline Assessment
- 9.1 Overview
- 9.2 Promising Drugs in Clinical Development
10 Current and Future Players
- 10.1 Overview
- 10.2 Trends in Corporate Strategy
- 10.3 Johnson & Johnson
- 10.4 AbbVie
- 10.5 Takeda
- 10.6 Pfizer
- 10.7 Eli Lilly
- 10.8 EA Pharma
- 10.9 Galapagos
- 10.10 Bristol-Myers Squibb
- 10.11 Arena Pharmaceuticals
11 Market Outlook
- 11.1 Global Markets
- 11.2 US
- 11.3 5EU
- 11.4 Japan
- 11.5 Canada
- 12.1 Bibliography
- 12.2 Abbreviations
- 12.3 Methodology
- 12.4 Primary Research - KOLs and Payers Interviewed for This Report
- 12.5 Primary Research - Prescriber Survey
- 12.6 About the Authors
- 12.7 About GlobalData
- 12.8 Contact Us
- 12.9 Disclaimer